Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1784.8▲0.02%
as on 04:01PM, 24 Mar 2025
Sun Pharma Performance
Day's Low
Day's High
₹1,777.6Day's Price Range₹1,82052 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | + 10.61 % |
| 3 Month Return | -3.07 % |
| 1 Year Return | + 11.68 % |
| Market Stats | |
| Previous Close | ₹1,784.50 |
| Open | ₹1,794.50 |
| Volume | 11.82L |
| Upper Circuit | ₹1,962.95 |
| Lower Circuit | ₹1,606.05 |
| Market Cap | ₹4,28,233.31Cr |
Sun Pharma Fundamentals
P/E Ratio
37.42
PEG Ratio
3.53
Market Cap
₹4,28,233.31 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Mutual Fund Holdings of Sun Pharma
Sun Pharma Analyst Rating
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2051.84
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of14.96%
High
₹2450
Target
₹2051.84
Low
₹1475
Sun Pharma target price ₹2051.84, a slight upside of 14.96% compared to current price of ₹1784.8. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.10%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.33%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Sun Pharmaceutical Industries Ltd
Sun Pharma Shares Surge with Increased Trading Volume - 21 Mar, 2025
On March 21, 2025, Sun Pharmaceutical Industries saw a 2.03% increase in share price to Rs 1786.50, driven by significant trading volume, reflecting strong investor interest and positive sentiment in the stock.Sun Pharma Plans Experimental Drug for Obesity - 20 Mar, 2025
Dilip Shanghvi, Managing Director of Sun Pharmaceuticals, announced plans to introduce an experimental drug, Utreglutide, for obesity and type 2 diabetes within four to five years.Sun Pharma Acquires Antibe Therapeutics for Growth - 19 Mar, 2025
Sun Pharmaceutical Industries has completed its acquisition of Antibe Therapeutics for CAD 4.5 million, aiming to expand its global footprint. Additionally, Sun Pharma is developing its GLP-1 receptor agonist, Utreglutide, with trials expected this year.Sun Pharma Gains on Acquisition and Profit Growth - 18 Mar, 2025
Sun Pharmaceuticals saw a 1.2% rise in shares, crossing key levels, following a 1.14% increase after its subsidiary's acquisition of Antibe Therapeutics. The company reported a 15.04% rise in Q3 net profit.Sun Pharma Issues Recall for Morphine Sulfate Tablets - 16 Mar, 2025
Sun Pharmaceutical Industries has recalled 9,840 bottles of Morphine Sulfate extended-release tablets due to Failed Dissolution Specifications, initiating a Class II nationwide recall on February 6, 2025.Sun Pharma Exhibits Signs of Recovery and Momentum - 15 Mar, 2025
Sun Pharmaceutical Industries is demonstrating early recovery signs, with price action above key moving averages and bullish momentum indicators. Short-term targets are set at ₹1,750, with mid-term potential reaching ₹1,860.Sun Pharma Shows Positive Momentum with Strong Indicators - 14 Mar, 2025
Sun Pharma's share price continues to rally, forming a morning star pattern and sustaining above its 20-day SMA. Rising volumes indicate buying activity, while the RSI suggests increasing strength. Analysts recommend buying, holding, and accumulating the stock, with an expected upside of 1,750-1,800 and a downside support at 1,600.Sun Pharma's Strategic Acquisition Boosts Specialty Portfolio - 13 Mar, 2025
Sun Pharmaceutical Industries is enhancing its specialty portfolio through the acquisition of Checkpoint Therapeutics for $350 million, gaining access to a promising skin cancer treatment. ICICI Securities has upgraded the stock to Buy, anticipating significant growth in the specialty segment. The acquisition aligns with Sun Pharma's focus on dermatology and oncology, despite initial earnings impact.Sun Pharma Acquires Checkpoint Therapeutics for $355 Million - 10 Mar, 2025
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million, adding the FDA-approved drug UNLOXCYT to its oncology portfolio. The deal is expected to close in Q2 2025.HSBC Lowers Target Price for Sun Pharma Shares - 06 Mar, 2025
HSBC maintains a Buy rating on Sun Pharma but reduces the target price to ₹2,000 from ₹2,280. The brokerage remains optimistic about growth in the specialty drug segment, particularly for Ilumya, while cautioning about the uncertain launch timeline for Leqselvi, which could impact long-term growth. Strong fundamentals support Sun Pharma's position in dermatology and immunology.Sun Pharma to Launch New Obesity Drug Soon - 03 Mar, 2025
Sun Pharmaceutical, India's largest drugmaker, aims to introduce its experimental drug targeting obesity and type 2 diabetes within the next four to five years.Sun Pharma MD Discusses Tariff Impact on Prices - 28 Feb, 2025
Dilip Shanghvi, MD of Sun Pharma, expressed concerns about tariffs affecting medicine prices, indicating that costs will be transferred to consumers.Sun Pharma Faces Challenges in Specialty Portfolio - 27 Feb, 2025
Sun Pharmaceuticals may encounter greater challenges in its specialty portfolio compared to US generics due to high price points. However, limited alternatives for its specialty products could offer some protection.Sun Pharma Collaborates on Key Drug Marketing - 25 Feb, 2025
Sun Pharmaceuticals is collaborating with Dr. Reddy's Laboratories to market second brands of vericiguat and finerenone, enhancing its presence in critical therapeutic areas.Sun Pharma Faces Pressure Amid Tariff Concerns - 24 Feb, 2025
Sun Pharmaceuticals is experiencing a decline in stock price, dropping for five consecutive sessions. JM Financial maintains a buy rating with a target of Rs 2115, despite concerns over US tariffs affecting investor sentiment.Sun Pharma Seeks Approval for Major Transactions - 20 Feb, 2025
Sun Pharmaceuticals Industries Ltd is seeking shareholder approval for approximately $1 billion in related-party transactions, including significant funding for its U.S. subsidiary. This follows penalties imposed on directors for past non-disclosures.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, SUNPHARMA stock has moved up by 8.8%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 71.0% return, outperforming this stock by 59.3%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 127.9% return, outperforming this stock by 31.6%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
Sun Pharma News
Sun Pharmaceutical Industries Shares Surge 2.03% Amid Volume Shocker
Sun Pharmaceutical Industries experienced a notable surge in todays session, climbing 2.03% to reach Rs 1786.50. The stocks movement was marked by a significant increase in trading volume, catching the attention of investors and analysts alike. The surge in volume, relative to its 20-day trading average, suggests heightened market interest and potential accumulation. The stock is currently included in several key indices, including the NIFTY 500, Nifty50 USD, NIFTY 50, NIFTY 100, NIFTY PHARMA, Nifty 200, NIFTY50 VALUE 20, NIFTY LargeMidcap 250, NIFTY Alpha Low-Volatility 30, Nifty Healthcare Index, Nifty LargeMidcap 250, Nifty500 Multicap 50:25:25, Nifty India Manufacturing, and Nifty Total Market. This broad index inclusion reflects the companys significant market presence and influence across various sectors. Revenue: Dec 2023: Rs 12,380.70 Cr Mar 2024: Rs 11,982.90 Cr Jun 2024: Rs 12,652.75 Cr Sep 2024: Rs 13,291.39 Cr Dec 2024: Rs 13,675.46 Cr Net Profit: Dec 2023: Rs 2,568.03 Cr Mar 2024: Rs 2,666.59 Cr Jun 2024: Rs 2,871.25 Cr Sep 2024: Rs 3,030.67 Cr Dec 2024: Rs 2,917.54 Cr EPS: Dec 2023: Rs 10.50 Mar 2024: Rs 11.10 Jun 2024: Rs 11.80 Sep 2024: Rs 12.70 Dec 2024: Rs 12.10 Key Financial Ratios Basic EPS: Increased from Rs 15.70 in March 2020 to Rs 39.90 in March 2024. Book Value/Share: Rose from Rs 204.75 in March 2020 to Rs 279.69 in March 2024. ROE: Remained robust at 15.04% in March 2024. Debt to Equity: Maintained at a healthy 0.04 in March 2024. Recent sentiment analysis indicates a shift towards a more bullish outlook on Sun Pharmaceutical Industries. A historical rating from March 17, 2025, showed a Bullish sentiment with a close price of Rs 1704.30. By March 21, 2025, the sentiment had strengthened to Very Bullish, with the close price rising to Rs 1787.95. This positive shift in sentiment could be contributing to the increased investor interest and the recent price surge. The companys financial performance reveals a consistent growth trajectory over the past several quarters. Heres a snapshot of key financials: The annual financial data further underscores this growth, with revenue increasing from Rs 32,837.50 Cr in 2020 to Rs 48,496.85 Cr in 2024. Net profit also saw a substantial rise from Rs 4,186.79 Cr in 2020 to Rs 9,648.44 Cr in 2024. Similarly, the Earnings Per Share (EPS) has grown from Rs 15.70 in 2020 to Rs 39.90 in 2024. Analyzing key financial ratios provides additional insights into the companys performance: Valuation ratios indicate a P/E of 40.62, a P/B of 6.11, and a P/S of 8.02 as of March 2024. With Sun Pharmaceutical Industries currently trading at Rs 1786.50, the stock has demonstrated strong momentum, supported by positive sentiment and robust financial performance, making it a key stock to watch in the pharmaceutical sector.21 Mar, 2025 03:33 PMSignificant Volume Surge in TBO Tek and Other Stocks on March 21
Sun Pharma Advanced Research Company Ltd clocked volume of 11.33 lakh shares by 10:48 IST on BSE, a 4.11 times surge over two-week average daily volume of 2.76 lakh shares. The stock gained 1.52% to Rs.146.70. Volumes stood at 9.24 lakh shares in the last session.21 Mar, 2025 11:00 AMEli Lilly Launches Mounjaro in India, Shares Rise
Competition is emerging from Indian pharmaceutical firms such as Sun Pharma, Cipla, Dr. Reddy's, and Lupin. These companies are working on developing generic versions to capture a share of what is projected to be a $150 billion global market within the next decade.21 Mar, 2025 01:12 AMSun Pharma Financials
Sun Pharma Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (37.42x)
March 24, 2025
Industry (53.98x)
March 24, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.34%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,28,233.31 Cr | 82.68% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,56,910.51 Cr | 41.31% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,715.76 Cr | 53.55% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹41,936.96 Cr | 5.72% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹26,529.08 Cr | -2.3% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceutical Industries Ltd
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1784.8, Open: ₹1794.5, Previous Close: ₹1784.5, High: ₹1820, Low: ₹1777.6, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 11.82L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹428233.31Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1784.8. It is down -8.96% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1784.8. It is up 29.60% from its 52 Week Low price of ₹1377.2